Haemonetics Corp Dossier
Qualitative Analysis
Business overview
Haemonetics Corporation is a global healthcare company that provides a suite of innovative medical technology solutions focused on blood and plasma component collection, surgical suite applications, and hospital transfusion services. The company operates through three primary business segments: Plasma, Blood Center, and Hospital. Haemonetics' business model centers on building a robust installed base of proprietary devices (such as the NexSys PCS plasma collection system and TEG hemostasis analyzers) to drive high-margin, recurring sales of single-use disposables, cartridges, and integrated software solutions. Geographically, the United States remains its most critical economic market, particularly for plasma collection and hospital-based interventional procedures.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A restructuring initiative approved in May 2025 to optimize operational performance and reduce costs by focusing on high-growth markets and geographies.
Expected impact: Anticipated annual savings of approximately $30 million upon full completion.
Consolidation of reportable segments from three to two, combining Plasma and Blood Center into 'Apheresis' and renaming the Hospital segment to 'MedSurg' to better align external reporting with internal resource allocation.
Expected impact: Improves operational transparency and aligns financial reporting with core business technologies and markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquiring pioneering next-generation technology for percutaneous vessel closure, specifically the PerQseal Elite system, to expand vascular closure offerings into large-bore structural heart and endovascular procedures.
Financial impact: Includes an upfront cash payment of €100 million (approximately €52 million net of previous investments/loans) and up to €85 million in contingent consideration based on sales growth and milestones.
Acquisition of the manufacturer of the ensoETM proactive esophageal cooling device used during RF cardiac ablation procedures, expanding the Hospital business unit's portfolio in electrophysiology.
Financial impact: Upfront cash payment of $160 million at closing plus additional contingent consideration tied to sales growth and milestones.